Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyeswith typical exudative age-related macular degeneration with good baseline visual acuity. Methods: This retrospective observational case series included 18 eyes (18 patients) with typical exudativeage-related macular degeneration with a baseline best-corrected visual acuity of 20 / 25 or better. Patientswere treated with anti-vascular endothelial growth factor monotherapy during the 12-month follow-up period. Baseline visual acuity and central foveal thickness were compared to the values at 12 months. Results: Patients received an average of 4.4 ± 1.3 intravitreal anti-vascular endothelial growth factor injections. The mean logarithm of minimum angle of resolution visual acuity was 0.08 ± 0.04, 0.08 ± 0.07, 0.12 ± 0.09, and0.16 ± 0.11 at baseline, three months, six months, and 12 months, respectively. Visual acuity at 12 months wassignificantly worse than the baseline value at diagnosis (p = 0.017), and the mean central foveal thickness atthe defined time points was 270.2 ± 55.6, 204.4 ± 25.4, 230.1 ± 56.3, and 216.8 ± 48.7 μm, respectively. Thecentral foveal thickness at 12 months was significantly less than the baseline value at diagnosis (p = 0.042). Conclusions: Deterioration in visual acuity was noted in eyes with typical exudative age-related macular degenerationwith good baseline visual acuity, suggesting the need for close patient monitoring and prompt treatmenteven in patients with good baseline visual acuity.
Abstract
Purpose: To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyeswith typical exudative age-related macular degeneration with good baseline visual acuity. Methods: This retrospective observational case series included 18 eyes (18 patients) with typical exudativeage-related macular degeneration with a baseline best-corrected visual acuity of 20 / 25 or better. Patientswere treated with anti-vascular endothelial growth factor monotherapy during the 12-month follow-up period. Baseline visual acuity and central foveal thickness were compared to the values at 12 months. Results: Patients received an average of 4.4 ± 1.3 intravitreal anti-vascular endothelial growth factor injections. The mean logarithm of minimum angle of resolution visual acuity was 0.08 ± 0.04, 0.08 ± 0.07, 0.12 ± 0.09, and0.16 ± 0.11 at baseline, three months, six months, and 12 months, respectively. Visual acuity at 12 months wassignificantly worse than the baseline value at diagnosis (p = 0.017), and the mean central foveal thickness atthe defined time points was 270.2 ± 55.6, 204.4 ± 25.4, 230.1 ± 56.3, and 216.8 ± 48.7 μm, respectively. Thecentral foveal thickness at 12 months was significantly less than the baseline value at diagnosis (p = 0.042). Conclusions: Deterioration in visual acuity was noted in eyes with typical exudative age-related macular degenerationwith good baseline visual acuity, suggesting the need for close patient monitoring and prompt treatmenteven in patients with good baseline visual acuity.
참고문헌 (17)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Sun Young Lee, "The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 22(2), pp.92~99 (2008), 대한안과학회
- 조한주, "Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 26(3), pp.157~162 (2012), 대한안과학회[DOI]
- Mones J, "FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity", Graefes Arch Clin Exp Ophthalmol, 250, pp.1737~1744 (2012)
- Takahashi M, "Intravitreal bevacizumab for age-related macular degeneration with good visual acuity", Jpn J Ophthalmol, 54, pp.565~570 (2010)
- Axer-Siegel R, "Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity", Retina, 32, pp.1811~1820 (2012)
- Mori R, "Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity", Jpn J Ophthalmol, 57, pp.365~371 (2013)
- Shona O, "Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision", Clin Experiment Ophthalmol, 39, pp.5~8 (2011)
- Matsumiya W, "Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1year follow-up", BMC Ophthalmol, 13, pp.10~ (2013)
- Yamashiro K, "Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment", Am J Ophthalmol, 154, pp.125~136 (2012)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
- Liu TY, "Progression of lesion size in untreated eyes with exudative age-related macular degeneration:a meta-analysis using Lineweaver-Burk plots", JAMA Ophthalmol, 131, pp.335~340 (2013)
- Arias L, "A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration", Retina, 29, pp.1444~1449 (2009)
- You JY, "Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography", Curr Eye Res, 37, pp.438~445 (2012)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Dadgostar H, "Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration", Ophthalmology, 116, pp.1740~1747 (2009)
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results", Ophthalmology, 119, pp.1388~1398 (2012)